What is MVP Mode in Medtronic Pacemaker System

Example of MVP Mode of Pacemaker

Case:

A 68-year-old male received dual chamber pacemaker sinus node dysfunction with syncope.

The pacemaker tracing shown below was obtained 4 weeks postimplant:

Device settings:

• Mode: AAIRóDDDR

• Pacing rate: 60 to 130 bpm

• Paced #AV delay: 200 ms

• Sensed AV delay: 170 ms

Why there variation in the AV delay?

The programmed mode is indeed #MVP, in which the device switches between #AAIR to DDDR depending on the presence of intrinsic R waves.

Managed Ventricular Pacing (MVP) is a pacing mode in some Medtronic pacemakers, ICDs, and CRT-D devices that reduces unnecessary right ventricular pacing.

In this mode, when the device is in AAIR and believes an atrial paced event is not followed by a ventricular sensed event, the device allows for this loss of conduction to occur once, and then follows with an atrial paced/ventricular paced event with a shortened paced AV delay of 80 ms The device then stays in AAIR mode and allows for an atrial paced event again with no ventricular intrinsic conduction.

If 2 of 4 events occur with no ventricular conduction, the device switches to DDDR mode. After 1 minute of DDDR, the device

will search for intrinsic conduction. If there is none, the device remains in DDDR mode for 2 minutes, rechecking again. This exponentially increases until the interval reaches 16 hours, at which time the device

will continue to check every 16 hours until the mode is reprogrammed.

Note that the paced QRS complexes in events 2, 6, and 8 with the shorter-paced AV delay of 80 ms result in a captured ventricular paced complex, while the longer paced AV delay of 200 ms in events 9 to 13

results in a slightly fused ventricular paced complex. This is because the shortened AV delay fully captures the ventricle, but the

longer AV delay allows intrinsic AV conduction resulting in fusion of the paced and sensed complexes.

Comments

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚 in Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts. The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

2025 ESC Guidelines on INR Targets in Mechanical Valves

2025 ESC Guidelines on INR Targets in Mechanical Valves INR Targets in Patients With Mechanical Heart Valves Updated, guideline-oriented review Mechanical heart valves are inherently thrombogenic and require lifelong anticoagulation. Vitamin K antagonists, particularly warfarin, remain the standard therapy. The international normalized ratio (INR) is used to guide anticoagulation intensity and must be individualized based on valve type, valve position, and patient-related thromboembolic risk factors. Subtherapeutic INR increases the risk of valve thrombosis and systemic embolism, whereas excessive anticoagulation increases bleeding risk. Why INR control is critical Mechanical valves promote thrombosis due to non-physiological blood flow, high shear stress, and continuous contact between blood and artificial surfaces. These prothrombotic mechanisms persist for life. Direct oral anticoagulants are contraindicated in mechanical valves; therefore, VKAs remain mandatory. The goal of I...

Dr. Usman's Cardiology Notes

Search This Blog